Related Experiment Video
Updated: May 2, 2026
Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Outcome and cost analysis of induction immunosuppression with IL2Mab or ATG in DCD kidney transplants
Reena Popat1, Asim Syed, Carmelo Puliatti
11 Department of Renal Transplant Unit, Royal London Hospital, London, UK. 2 Address correspondence to: Asim Syed, Renal Transplant Unit, 9th Floor, Royal London Hospital, Whitechapel Road, London, E1 1BB.
Background:
Kidney transplantation from DCD now represents a significant part of the overall transplant activity in the UK. Outcome of different induction immunosuppression regimes and related cost benefit analysis has been reported by very few studies.This is a single centre study on frequency-matched patients who received a DCD kidney transplant between August 2007 and August 2009.
Methods:
Data on 45 patients divided in 2 groups were collected prospectively and analyzed retrospectively. Group A (24 patients) received IL2Mab and Group B (21 patients) ATG as induction immunosuppression. Patient and graft survival were similar in both groups.
Results:
In the ATG-induced group, there was a significant lower rate of DGF, BPAR, and infections requiring readmission.A cost analysis was performed including all immunosuppression-related costs, and it has shown remarkable savings in the ATG-induced group.
Conclusion:
Considering that the number of DCD kidney transplants is destined to rise in the UK, we believe that ATG is a valid option to continue optimizing outcomes of DCD kidney transplant. In our experience, ATG proved to be safe, effective, and contributed to significant cost savings.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
01:28Kidney Transplant I: Introduction